The pharmacokinetics of the kininogens.
Recent evidence has shown that plasma high molecular weight kininogen and both kininogens have the ability to modulate prekallikrein activation and thrombin-induced platelet activation, respectively. However, nothing is known about the plasma clearance and tissue distribution of these proteins. We examined the in vivo pharmacokinetics of high (HK) and low (LK) molecular weight kininogens in rats. 125I-HK and -LK molecular weight kininogens' clearance in rats best-fitted a biexponential model. For HK, the t1/2alpha and t1/2beta were 0.6 and 9.5 h and for LK, 0.78 and 7.4 h, respectively. 125I-kinin-free HK (cleaved HK) was cleared with a t1/2alpha and t1/2beta of 0.45 and 9.9 h, respectively. 125I-Domain 3 of kininogens was cleared with a t1/2beta and t1/2c of 0.99 and 13.3 h, respectively. HK was mostly concentrated in lung; LK, domain 3, and cleaved HK were mostly concentrated in kidney. The kininogens were also concentrated in liver, spleen, and skin. These studies indicate that protein size rather than form is the major determinant of its clearance. Furthermore, the distribution of the kininogens is where bradykinin metabolism and activity are well described.
Schmaier
A H
AH
Department of Internal Medicine, University of Michigan, Ann Arbor 48109-0640, USA. aschmaie@umich.edu
Wahl
R
R
Fisher
S J
SJ
Brenner
D
D
D000818:Animals; D005260:Female; D019679:Kininogen, High-Molecular-Weight / Q000493:pharmacokinetics*; D019728:Kininogen, Low-Molecular-Weight / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution
D019679:Kininogen, High-Molecular-Weight; D019728:Kininogen, Low-Molecular-Weight